Rafaèle Elisabeth Tordjman

ALLERGAN MEDICAL GmbH develops medical devices and implants. The company was founded in June 1998 by Nikolaos Stergiopulos and is headquartered in Ecublens, Switzerland.

Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco.

Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

PregLem SA manufactures and markets pharmaceutical products specializing in gynecology and women's reproductive health. Its products include ESMYA, PGL2001, and PGL1001. The company was founded in June 2006 and is headquartered in Geneva, Switzerland.

ENYO Pharma SA operates as a biopharmaceutical company. The firm's research and development is focused on human infecting viruses, with the first two programs being dedicated to the treatment of severe and seasonal flu and chronic hepatitis B. The company was founded by Jacky Vonderscher, Jean-Jacques Garaud, Benoît de Chassey, Laurène Meyniel-Schicklin, Patrice André and Vincent Lotteau January 2014 and is headquartered in Lyon, France.

CoreValve SA develops implants and instruments for heart surgery. It offers aortic bioprostheses, delivery catheters, disposable loading systems and other related products. The company was founded by Jacques Seguin in 2001 and is headquartered in Paris, France.

Medtronic CoreValve LLC develops transcatheter technologies for failing aortic heart valves. Its proprietary ReValving System allows both percutaneous (PAVR) and transapical aortic valve replacement (TAVR) and is intended to provide an alternative to open-heart surgery. The company was founded by Jacques Seguin in 2001 and is located in Irvine, CA.

Women Innovating Together In Healthcare operates as an organization of accomplished women. The private company is based in Paris, France. The French company was founded by Rafaèle Elisabeth Tordjman.

Healthcare Brands International (HBI) is a new company, established in the UK in October 2006, and participating primarily in the growing market of OTC Medicines. The company is committed to acquiring, developing and investing in differentiated healthcare products. In short it will translate innovative science into meaningful consumer brands. Funded with over £100 million of venture capital from leading international venture capital investors, the company is a team of experienced OTC blue chip business professionals with an unrivalled network of partners and contacts around the world (with particular strength in Europe). It brings core skills in consumer marketing and brand development and combine with partners providing in-market operational and regulatory expertise. It will focus on innovative products with meaningful and substantiated differentiation that meet a relevant and yet unmet or only partially met consumer need and thereby help grow the overall self-medication market.

Innoskel SASU is a French bioscience platform company that aims to improve the quality of life of patients with severe rare bone disorders. Innoskel is based in Valbonne, France, and was founded by Elvire Gouze, who has been the CEO since incorporation. The company achieves this goal through patient centricity, scientific innovation, and operational excellence. Innoskel is developing transformative therapies for the unmet needs of individuals with rare bone disorders, with a focus on type II collagen disorders. The company's lead asset is INS-101, a gene therapy that has shown strong efficacy in preclinical studies.

Alentis Therapeutics AG develops novel medications to treat advanced liver diseases and cancers. The company was founded by Neil Goldsmith on March 1, 2019 and is headquartered in Basel, Switzerland.

CDR-Life Inc. is a Swiss biotherapeutics company that develops novel immunotherapies to target the power of the immune system specifically to tumor cells. CDR-Life is based in Schlieren, Switzerland, and was founded in 2017 by Leonardo Borras, Christian Leisner, Dominik Escher, Rouven Bingel-Erlenmeyer, and Konstantin von Schulthess. The company's proprietary antibody platform targets intracellular tumor antigens presented on the major histocompatibility complex (MHC) with high affinity and specificity, which allows them to develop a pipeline of first-in-class therapeutics across a broad range of solid tumors. The company is backed by leading cross-Atlantic investors and has an existing collaboration and licensing agreement with Boehringer Ingelheim for a novel antibody fragment therapy to treat macular degeneration. Christian Leisner has been the CEO since 2017.